Marengo Therapeutics Announces Treatment of First Patient in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602 in Cancer Patients Refractory to Anti-PD1 Therapy | DNA RNA and cells
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ fusion Antibody Molecule STAR0602, in Cancer Patients Refractory to...